1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Mangalam Drugs & Organics Ltd.

Mangalam Drugs & Organics Ltd.

29.57
INR
-0.85
(-2.79%)
-24.16EPS
445.41MMarket Cap
Mangalam Drugs & Organics Ltd.
NSE:MANGALAM
(National Stock Exchange of India)

Recent

price

29.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
96.66
116.24
95.05
92.97
167.39
205.19
192.26
176.36
141.49
178.3
239.95
282.64
231.21
230.91
199.13
145.5
146.6
Revenue per Share
1.58
0.48
-8.95
-2.31
4.66
11.15
14.07
12.57
-5.07
5.21
17.67
12.42
0.8
-5.73
4.25
-28.05
-24.16
Basic EPS, GAAP
-3.32
0.59
-2.13
3.93
7.7
7.45
2.07
5.42
7.8
14.92
-2.46
-1.24
7.33
-5
14.15
-4.88
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
0.5
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
28.4
28.88
19.93
17.62
22.28
43.17
54.15
65.56
60.44
65.67
82.63
95.12
96
85.79
94.12
65.11
- -
Book Value per Share
28.4
28.88
19.93
17.62
22.28
43.13
54.12
65.08
58.06
61.79
76.34
86.42
84.48
67.79
74.88
44.27
- -
Tangible Book Value per Share
13
13
13
13
13
14
16
16
16
16
16
16
16
16
16
16
16
Basic Weighted Avg Shares
1,274
1,532
1,253
1,225
2,206
2,950
3,043
2,792
2,239
2,822
3,798
4,474
3,660
3,655
3,152
2,303
2,320
Sales/Revenue/Turnover
7.74
7.38
-5.41
4.76
7.38
11.33
13.7
14.43
1.18
5.5
11.7
8.66
3.99
0.29
5.33
-14.03
-11.56
Operating Margin (%)
33
37
39
40
42
44
50
66
75
82
92
102
110
75
166
182
178
Depreciation Expense
21
6
-118
-30
61
160
223
199
-80
83
280
197
13
-91
67
-444
-382
Net Income, GAAP
30.48
44.31
- -
- -
- -
33.24
28.56
32.23
- -
- -
29.22
29.12
42.63
- -
- -
- -
- -
Effective Tax Rate (%)
1.64
0.41
-9.42
-2.48
2.78
5.43
7.32
7.13
-3.59
2.92
7.36
4.39
0.35
-2.48
2.13
-19.28
-16.48
Profit Margin (%)
67
74
143
100
166
269
180
230
142
97
248
549
412
119
74
-409
- -
Working Capital
192
220
439
402
394
169
169
111
105
50
101
303
255
185
117
86
- -
LT Debt
374
381
263
232
294
621
857
1,038
957
1,039
1,308
1,506
1,520
1,358
1,490
1,031
- -
Total Equity
8.23
7.02
- -
- -
- -
20.07
21.69
17.4
- -
- -
17.65
12.46
3.47
- -
- -
- -
- -
Return on Invested Capital (%)
2.51
0.71
- -
- -
- -
18.22
19.76
15.85
- -
- -
18.21
11.28
2.67
- -
- -
- -
- -
Return on Capital (%)
5.31
1.68
-36.69
-12.28
23.36
35.07
30.15
20.99
-8.05
8.27
23.83
13.97
0.84
-6.31
4.72
-35.23
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,042
- -
LT Borrowings
- -
75
- -
LT Finance Leases
- -
11
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
435
430
445

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,557
- -
Cash, Cash Equivalents & STI
- -
39
- -
Accounts Receivable, Net
- -
403
- -
Inventories
- -
1,028
- -
Total Current Liabilities
- -
1,966
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,042
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.01%
-3.14%
-30.82%
Free Cash Flow
-131.58%
-285.47%
-134.48%
Net Income, GAAP
-194.83%
-374.46%
-760.65%
Sales/Revenue/Turnover
-0.55%
-8.25%
-26.93%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
765
798
886
728
3,152
2026
572
493
584
673
2,303
2027
571
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.7
1.7
0.81
0.04
4.25
2026
-8.72
-4.64
-6.21
-8.48
-28.05
2027
-4.83
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Mangalam Drugs & Organics Limited manufactures active pharmaceutical ingredients (APIs), intermediates, specialty chemicals, organic and inorganic chemicals; and provides regulatory services to pharmaceutical companies worldwide. The company produces anti-malarial APIs including artemether, lumefantrine, and artemisinin-based compounds; cardiovascular products such as atorvastatin calcium; antiviral agents like acyclovir and dolutegravir sodium; central nervous system drugs including aripiprazole, risperidone, olanzapine, and etodolac; and perfumery chemicals such as l(+)menthol and phthalazine-1,4-dione. It operates multi-product manufacturing facilities in Vapi, Gujarat, and additional sites in India, with an in-house Research & Development laboratory recognized by the Department of Scientific & Industrial Research, Government of India. Founded in 1972 and headquartered in Mumbai, Maharashtra, Mangalam Drugs & Organics Limited serves global markets in Asia, Africa, Europe, and the Americas, positioning itself among Asia's top producers and the world's largest for select anti-malarial APIs. The company maintains certifications including WHO-Geneva GMP, EDQM, MFDS Korea, and ANVISA approvals for its plants, and holds an ongoing agreement with the Clinton Health Access Initiative under its Fight Malaria Program for anti-malarial API supply. In recent developments, Mangalam Drugs & Organics Limited inks a technology transfer deal with Emzor Pharmaceutical Industries Limited for four anti-malarial APIs to support manufacturing in Africa. The company agrees to acquire Shri JB Pharma LLP in March 2024 via a scheme of merger involving issuance of 265 equity shares, pending National Company Law Tribunal and stakeholder approvals. It achieves WHO prequalification for dolutegravir sodium (non-micronised and micronised forms) in October 2020 and participates in the Medicines Patent Pool pledge with 17 other generic manufacturers to accelerate COVID-19 interventions for low- and middle-income countries.